Introduction
============

Squamous cell oropharyngeal carcinoma is a disease with a rising incidence in various Western countries ([@b1-ol-0-0-6152]). This increase is primarily due to a high number of human papillomavirus (HPV)-associated tumors in the tonsils and at the base of the tongue ([@b1-ol-0-0-6152],[@b2-ol-0-0-6152]). It has been established that HPV squamous cell cancer has an improved diagnosis and clinical outcomes, as compared with HPV-negative tumors ([@b1-ol-0-0-6152]--[@b3-ol-0-0-6152]).

Squamous cell cancer in the tonsils and at the base of the tongue is often diagnosed in an advanced loco-regional phase, which is stage III--IVB ([@b1-ol-0-0-6152]). Squamous cell carcinoma treatments at these stages may use various modes, including combining surgery with chemoradiotherapy (CTRT) or primary CTRT followed by rescue surgery ([@b4-ol-0-0-6152]). A review of the literature revealed that patients treated with combined modes typically reported a low quality of life (QoL), with severe consequences following surgery, radiotherapy and chemotherapy, in the short and in the long-term ([@b5-ol-0-0-6152],[@b6-ol-0-0-6152]). The decrease in the QoL of patients treated with high-intensity multi-modal strategies highlights the necessity of modifying treatments, particularly for young HPV-positive patients, where an increased survival rate has already been reported. ([@b1-ol-0-0-6152],[@b3-ol-0-0-6152],[@b7-ol-0-0-6152],[@b8-ol-0-0-6152]). The modified treatment for HPV-positive tumors in the tonsils and at the base of the tongue is based on the deintensification of current therapies, with the aim of reducing toxicity and, therefore, improving long-term QoL, whilst also maintaining therapeutic effectiveness ([@b3-ol-0-0-6152],[@b9-ol-0-0-6152]).

To date, few studies have analyzed the QoL for long-term survival patients who were treated with combined therapy for oropharyngeal squamous cell cancer in the tonsils or at the base of the tongue ([@b10-ol-0-0-6152]). The incidence of oropharyngeal squamous cell cancer is increasing in Western countries, by contrast with a decrease in the incidence of other types of carcinoma in alternate cervicofacial regions, despite a reduced smoking prevalence ([@b1-ol-0-0-6152]). Infection with HPV, particularly HPV type 16, is currently considered to be an important factor for the insurgency of HPV-positive oropharyngeal carcinomas, which exhibit various radiological, epidemiological, clinical, anatomical, biological and prognostic features, when compared with HPV-negative carcinomas ([@b3-ol-0-0-6152],[@b11-ol-0-0-6152]). The only region in the cervicofacial area with a demonstrated viral etiological connection is the oropharynx ([@b3-ol-0-0-6152],[@b8-ol-0-0-6152]). These studies raise certain questions about the choice of therapy and the intensity of treatment that should be used depending on the stage of the HPV tumor ([@b12-ol-0-0-6152],[@b13-ol-0-0-6152]).

The aim of the present study was to evaluate the QoL of patients with a long-term survival, who were treated with combined therapy for squamous cell tumors in the tonsils and at the base of the tongue, and then to compare the QoL results reported by patients who were HPV-positive and HPV-negative. As HPV is associated with an improved response to treatment and a greater survival time, it was hypothesized that patients with HPV-high-risk (HR)-associated oropharyngeal squamous cell carcinoma may have an improved QoL. Understanding the association between the HPV status and the post-treatment QoL may improve the management of patients with squamous cell HPV-HR-associated carcinoma and potentially enable the development of personalized therapy, in order to optimize not only the survival rate, but also the QoL for each patient.

Materials and methods
=====================

### Patients

The present study involved multicenter research, as the patients were recruited and attended follow-ups at either the Ear, Nose and Throat (ENT) Department of the University of Trieste (Trieste, Italy), the ENT Unit of Treviso Hospital (Treviso, Italy), University of Padua (Padua, Italy), the Interhospital ENT Department of the Province of Venice (Venice, Italy) or the ENT Department of the University of Catania (Catania, Italy).

The present cross-sectional study used the following inclusion criteria: The presence of a squamous cell tumor in the tonsils or at the base of the tongue at stage III--IVB; patients who had not previously been treated for squamous cell tumors in the tonsils or at the base of the tongue, regardless of the correlation with HPV; treatment that includes surgery alone or plus CTRT, or primary CTRT ± rescue surgery; complete remission following treatment; treatment was completed ≥60 months prior to being included in the present study; patients who exhibited signs of remission following the completion of the questionnaire.

A total of 48 patients, 34 males (71%) and 14 females (29%), were recruited for the present study. The age ranged between 40--79 years old at the time of diagnosis. All the recruited patients signed an informed consent. Among the cases collected from the various recruitment centers, each had a survival time of ≥5 years following treatment for oropharyngeal squamous cell carcinoma; those patients with stage I/II disease, with oropharyngeal carcinoma not associated with the tonsils or the base of the tongue, or who were not completely recovered from the disease were not included. The patient clinical features, tumor sub-region, tumor-node-metastasis (TMN) grade stage and HPV status are summarized in [Table I](#tI-ol-0-0-6152){ref-type="table"}. The number of recruited cases, considering the age at the time of diagnosis, is summarized in [Table II](#tII-ol-0-0-6152){ref-type="table"}.

### Questionnaires

QoL was evaluated using questionnaires prepared by the European Organization for the Research and Treatment of Cancer (EORTC), in particular using the general questionnaire analyzing QoL: QoL Questionnaire-Core 30 (QLQ-C30) and the specific questionnaire for the head and neck area (35/QLQ-H&N35) ([@b14-ol-0-0-6152],[@b15-ol-0-0-6152]). These questionnaires were completed during follow-up appointments or under specific doctor\'s request, in person or over the phone. The results of the QoL questionnaires were analyzed according to the specific scoring manual provided by the EORTC ([@b16-ol-0-0-6152],[@b17-ol-0-0-6152]), all scores were expressed on a scale ranging between 0--100.

### Laboratory examination

For molecular analysis formalin-fixed paraffin-embedded (FFPE) tumor samples were used. All tumor samples were tested for the presence of HPV and details of the method are already published in Baboci *et al* ([@b18-ol-0-0-6152]). Briefly, DNA was extracted and amplified through broad spectrum L1 multiplex human papillomavirus genotyping (BS-L1-MPG assay) ([@b19-ol-0-0-6152]). In total, \~150 bp for the gene L1 of \~51 types of mucosal HPV were amplified. Detection of the human β-globin gene was used as a control for the quality of DNA, as well as a control for polymerase chain reaction (PCR).

The DNA samples were also analyzed using MY09/11-PCR amplification, followed by Restriction Fragment Length Polymorphism and direct sequencing ([@b20-ol-0-0-6152]). Additionally, the expression of p16 protein was immunohistochemically analyzed from the same FFPE tumor samples. Due to limited sample availability, p16 protein expression was analyzed in 29 patients using CINtec^®^ p16^INK4a^ Histology, ready-to-use mouse monoclonal antibody (clone E6H4™; cat.no. 06695248001; Roche Diagnostics, Basel, Switzerland) on Automated immunohistochemistry stain Ventana BenchMark Ultra (Roche Diagnostics). Sections of tissue (2--4 µm) were deparaffinized with Ez-Prep 1X for 25 min at 72°C (cat. no. 05279771001; Roche Diagnostics). Subsequently, on-board heat antigenic retrieval was performed for 36 min at 95°C in Ultra CC1 (Tris-Borate-EDTA pH 8.2; cat. no. 05424569001; Roche Diagnostics) ([@b21-ol-0-0-6152],[@b22-ol-0-0-6152]). Slides were left to cool on-board by the system for 4±1 min. Endogenous peroxidase enzymes were blocked with 3% hydrogen peroxide for 4 min at 36°C (UltraView Universal DAB Inhibitor). The slides were incubated with the CINtec^®^ p16^INK4a^ Histology primary antibody for 24 min at 36°C. Detection was then performed on-board with Ultraview DAB Detection kit (cat. no. 05269806001; Roche Diagnostics). UltraView DAB Detection kit Universal horseradish peroxidase-conjugated Multimer, α-mouse/rabbit secondary antibody was added and incubated for 8 min at 36°C. Subsequently, the signal was revealed with a chromogen-substrate solution (DAB plus H2O2; Roche Diagnostics) for 8 min at 36°C, followed by a signal enhancer step for 4 min at 36°C with copper sulfate. Final counterstain was performed using hematoxylin. Tissues positive for p16 were defined by clear and dispersed nuclear and cytoplasmic staining in ≥70% of tumor cells. Cervical HPV-positive tissue sections were used as positive controls and negative controls were produced by omitting the primary antibody ([@b19-ol-0-0-6152]).

### Statistical analysis

Descriptive statistics were computed for all functioning and symptoms scale scores ([Table III](#tIII-ol-0-0-6152){ref-type="table"}). A multivariate analysis of variance (MANOVA) approach was used to determine whether a number of interconnected and dependent variables, the scales of the QoL-C30 and those of the H&N35, were influenced by the five following independent variables: i) HPV positivity (positive vs. negative); the 12 participants whose information was unavailable were excluded from the analysis that included HPV as a factor. ii) The type of treatment received by the patient (surgery vs. CTRT, vs. surgery and RT, vs. surgery and CTRT). It must be acknowledged that, concerning the analysis that included the type of treatment as an independent variable, no patients who were exclusively treated with RT without surgery were included. iii) The stage of the disease (III vs. IV); with regards to this predictor, no distinction was made between stage IVA and IVB, as only one patient was reported to have stage IVB disease. iv) The patient gender (male vs. female). v) The age of the patient at the time of diagnosis (\<60 vs. ≥60 years).

In the prediction of the QLQ-C30 and H&N35 scales, the five independent variables were included separately in each MANOVA, using the Wilks\'s λ statistic test ([@b23-ol-0-0-6152],[@b24-ol-0-0-6152]). The approximate F distribution was used to evaluate the impact of each independent variable with a statistical significance threshold of α=0.05. The results of this analysis are reported in [Table IV](#tIV-ol-0-0-6152){ref-type="table"}. Follow-up analyses were performed using unequal variances t-tests ([Table V](#tV-ol-0-0-6152){ref-type="table"}). All analyses were performed using R statistical language software (version 3.3.1) ([@b16-ol-0-0-6152],[@b17-ol-0-0-6152]).

Results
=======

### Descriptive statistics of patients

A total of 48 patients were enrolled and analyzed in the current study, including 71% males and 29% females. The age descriptive statistics are reported in [Table II](#tII-ol-0-0-6152){ref-type="table"}. When considering the stage of the disease and the subregion, 16 patients were determined to have stage III disease and 32 patients had stage IV disease. Overall, 46% of the cases involved the tonsil region, 40% involved the base of the tongue and 14% involved both of the subregions. The immunohistochemical data indicated the presence of HPV in 40% of the patients.

[Table III](#tIII-ol-0-0-6152){ref-type="table"} reports the descriptive statistics of the 15 QoL C30 scales and of the 18 H&N35 scales. The functioning scale with the lowest average score was global QoL ([@b15-ol-0-0-6152],[@b16-ol-0-0-6152]), whereas the functioning scale with the highest score was on the cognitive functions scale. The symptom with the highest average self-reported score in the QLQ-C30 survey was C30-SL (insomnia) ([@b14-ol-0-0-6152],[@b16-ol-0-0-6152]), followed by C30-FI (financial difficulties) and by C30-CO (constipation) ([@b14-ol-0-0-6152],[@b16-ol-0-0-6152]). In the H&N35 questionnaire, the symptoms with the highest self-reported scores were dry mouth, sticky saliva and use of painkillers ([@b15-ol-0-0-6152],[@b16-ol-0-0-6152]).

### Variables associated with HR-QoL

[Table IV](#tIV-ol-0-0-6152){ref-type="table"} reports the results of MANOVAs predicting the QLQ-C30 and the H&N35 scale scores. In the prediction of the QLQ-C30 scales, only one independent variable, the age of the patient at the time of the diagnosis, showed a significant effect, whereas no variables significantly predicted the H&N35 scales. The effect of age was followed-up with several t-tests, reported in [Table V](#tV-ol-0-0-6152){ref-type="table"}. Patients who were older than 60 at the time of the diagnosis tended to report worse physical functioning, worse role functioning, more constipation, and more appetite loss compared to patients that were \<60 years at the time of diagnosis.

Discussion
==========

There are several reasons to change treatment strategies in patients affected by HPV-induced OSCC, as the international guidelines on the treatment of HPV-associated oropharyngeal squamous cell carcinoma are currently the same as for non-HPV-associated OSCC. The patients are treated with surgery or RT in the early-stages, and with combined treatment in the advanced-stages ([@b4-ol-0-0-6152]). It currently appears that the success of the various approaches is similar, and that the treatment selection must be made with consideration of associated therapeutic morbidities and the long-term QoL ([@b25-ol-0-0-6152],[@b26-ol-0-0-6152]).

In the past few decades RT techniques have changed. Functional outcomes between Intensity Modulated Radio Therapy (IMRT) and standard 2D RT are controversial in the literature; however, it is unanimous on the best functional results on chewing functioning, swallowing difficulty, taste and xerostomia may be better or identical compared with standard 2D RT ([@b27-ol-0-0-6152],[@b28-ol-0-0-6152]). The anatomical structures spared by IMRT improve long-term effects with regard to swallowing, maintaining a local control of the disease. For these reasons, IMRT may be considered as a potential standard treatment for oropharyngeal carcinoma ([@b28-ol-0-0-6152]--[@b31-ol-0-0-6152]). Similarly, in patients treated with surgery in the early-stages, a long-term functional improvement may be observed, comparable with patients who received adjuvant RT following surgery of a primary tumor ([@b31-ol-0-0-6152],[@b32-ol-0-0-6152]).

Some scholars suggest that patients not treated with surgery have more problems concerning xerostomia, dental problems and taste, as compared with patients treated with isolated surgery or followed with adjuvant RT ([@b27-ol-0-0-6152],[@b32-ol-0-0-6152]). When comparing the results of the QoL questionnaire completed by patients exclusively treated with surgery with those of patients who received any type of RT treatment, the latter complained significantly of xerostomia and dental problems ([@b29-ol-0-0-6152],[@b32-ol-0-0-6152],[@b33-ol-0-0-6152]).

In the present study, 14 cases were treated with surgery followed by adjuvant RT; 13 cases were treated with surgery followed by CTRT; 10 cases were treated with sole CTRT and 10 cases were treated exclusively with surgery. According to the statistical analysis conducted in the present study, which omitted the single case of the patient who was treated exclusively with RT, the differences in general QoL and of the single scales that were analyzed are not correlated with the type of therapy selected for the treatment of the patient.

In the last three decades, pathological models of head and neck squamous carcinomas have changed. In particular, the incidence of HPV-associated tumors has increased, as compared with tumors associated with alcohol and tobacco consumption ([@b1-ol-0-0-6152],[@b33-ol-0-0-6152],[@b34-ol-0-0-6152]). It is well known that patients with high-risk HPV-associated oropharyngeal cancer have increased survival rates, suggesting a high response to RT ([@b13-ol-0-0-6152]). Immunohistochemical analysis of the results indicated that the presence of HPV in 40% of the patients involved in the present study was consistent with the data from the Memorial Sloan Kettering Cancer Center (MSKCC), where in 2000 in the USA are described 40% of HPV-induced oropharyngeal squamous cell carcinomas. While, the same study demonstrated an incidence increase of 60--70% in the United States of HPV-associated OSCC between 2010 and 2014 ([@b1-ol-0-0-6152]). The study of QoL, conducted by a group from the Fred Hutchinson Cancer Research Centre of Seattle and Washington, using questionnaires from Washington University, demonstrated how patients with high-risk HPV in the pre-treatment phase experience an improved QoL, as compared with patients with low-risk HPV or HPV-negative cases ([@b32-ol-0-0-6152]). Conversely, immediately following the surgery, the same patients with high-risk HPV reported a more significant decrease in QoL, as compared with patients with low-risk HPV and with patients who were HPV-negative. One year following the treatment, there were no significant differences in QoL observed among the patients, when considering the stage of HPV ([@b32-ol-0-0-6152]). These results suggest that a decrease in QoL immediately following surgery in patients with high-risk HPV may be due to the high intensity of the treatment administered in this population ([@b32-ol-0-0-6152],[@b35-ol-0-0-6152]). Deintensification of the treatment was suggested for patients with HPV-HR oropharyngeal squamous carcinoma, as they are typically younger and have an improved survival rate, compared with other patients with the same disease ([@b26-ol-0-0-6152]). The importance of determining the stage of HPV in patients with oropharyngeal carcinoma may lead to a deintensified therapeutic regiment for the patient, in order to optimize survival and QoL trajectories in this population ([@b26-ol-0-0-6152]).

Currently, standard treatments are also applicable in patients who are HPV-positive where robotic transoral surgery has revealed the greatest prognosis and functional results, even though the most effective therapy for HPV-associated carcinoma is still under discussion, and trans oral robotic surgery (TORS) or surgery associated with RT is able to provide a good level of QoL ([@b25-ol-0-0-6152]). With a combination of TORS and adjuvant therapy, the disease may be controlled both in HPV-positive and HPV-negative tumors. In particular, the benefits of this type of surgery appear to include good survival rates, allowing the reduction of the dose and volume of the following RT, in order to reduce long-term toxicity; this characterizes combined radical CTRT treatment. ([@b25-ol-0-0-6152],[@b26-ol-0-0-6152],[@b36-ol-0-0-6152]).

A number of studies aimed at evaluating the possible deintensification of current treatments able to be applied to the low-medium risk category of patients are in progress. Such deintensification may consist of a reduction of the radiation dose and/or alterations of the concomitant therapy; for example, avoiding chemotherapy and replacing it with a biological therapy, such as cetuximab, and introducing neoadjuvant chemotherapy in order to avoid concomitant chemotherapy. At this time, there is insufficient data to modify the selection of the therapy depending on the risk profile ([@b25-ol-0-0-6152],[@b31-ol-0-0-6152],[@b37-ol-0-0-6152],[@b38-ol-0-0-6152]).

Furthermore, it is necessary to reflect upon two further aspects: The type of laboratory tests conducted in order to evaluate the presence of HPV in patients, and the type of questionnaire provided to determine QoL.

Increasing evidence concerning the diagnostic role of HPV HR in oropharyngeal oncology, which is associated with a more favourable prognosis and a higher radiosensibility, suggests that it is required to identify useful molecular markers, which may be integrated into the clinical management of oropharyngeal SCC ([@b39-ol-0-0-6152]). The use of p16 in immunohistochemistry, as a marker to determine the presence of HPV, is controversial. For certain authors, it may be associated with a high rate of false-positive results, increasing the necessity for the identification of novel markers for the infection of oral HPV ([@b3-ol-0-0-6152],[@b9-ol-0-0-6152]); these studies suggest not relying exclusively on p16 for HPV screening ([@b3-ol-0-0-6152],[@b35-ol-0-0-6152]). The inconsistency of the methods currently used to identify molecular markers in the field of head and neck oncology, in particular for HPV infection, is one of the primary obstacles faced in clinical practice. For this reason, an agreement on the methods used to identify high-risk HPV in squamous cell carcinoma in head and neck oncology is essential ([@b3-ol-0-0-6152],[@b9-ol-0-0-6152],[@b19-ol-0-0-6152],[@b21-ol-0-0-6152],[@b39-ol-0-0-6152]).

Statistical analysis carried out on the patients involved in the current study, considering HPV-positivity to be an independent variable, indicated that it has no significant influence on the final QoL score, as compared with HPV-negative patients. These results appear to be concordant with those of the Seattle team study, which stated that one year following therapy the patient QoL was not statistically different between patients who were HPV-negative and HPV-positive ([@b35-ol-0-0-6152]). In the present study, the results on QoL correlated with HPV is justified as the patient sample considered had a long-term survival time ≥5 years; there are patients with survival times between 5--16 years (mean, 9.5 years) following treatment.

The EORTC questionnaire used ([@b14-ol-0-0-6152],[@b15-ol-0-0-6152]), as compared with the one proposed by Washington University, is more detailed in addressing the various aspects of activity, the body and social functions, allowing for a more specific evaluation, particularly with regards to swallowing and aspects of global health. The EORTC questionnaire is widely used due to its reliability and effectiveness ([@b14-ol-0-0-6152],[@b15-ol-0-0-6152]). Currently, there is no questionnaire available for this particular field that may be universally adopted for the improved analysis of variables, and also to interpret results with the same parameters.

In conclusion, completing the exposition of the data collected in the present study, it was determined that QoL is influenced by age in patients with a long-term survival time who were treated for oropharyngeal carcinoma at the base of tongue or in the tonsils. Scrutinizing the age variable with several t-tests, it emerged that patients who were older than ≥60 at the time of the diagnosis tended to report poorer physical functioning (questions 1--5 of the QLQ-C30 questionnaire), more severe limits to physical ability (questions 6 and 7 of QLQ-C30), more appetite loss (question 13 of QLQ-C30) and more constipation (question 16 QLQ-C30), as compared with younger patients. Since analyzed cases are taken in consideration from 5--16 years following treatment, and 69-years-old is the average age of patients in the present study, the results may be influenced by aging.

In conclusion, the available data supports the concept that oropharyngeal tumors have been increasing in incidence globally over the last 20 years, as compared with other types of head and neck-associated tumors, particularly in Western countries ([@b1-ol-0-0-6152]). With respect to the treatment of the disease and based on current understanding, HPV-positive oropharyngeal cancer may be considered a singular type of cancer in head and neck area with relatively favourable outcomes. Patients with HPV-positive oropharyngeal cancer are generally younger and in better health (less comorbidity). The presence of HPV type 16 may also be considered a prognostic marker for a higher rate of global survival with total recovery, but its predictive role has not yet been demonstrated ([@b38-ol-0-0-6152],[@b39-ol-0-0-6152]). Numerous questions regarding the natural history of HPV infections are still under discussion. The ineffectiveness of shared methods for identifying molecular markers for HPV infection is one of the primary obstacles to their use in clinical practice. For this reason, a consensus on the methods to be used for identifying high-risk HPV in squamous cell carcinoma in the head and neck area is required.

In the present study, QoL, taking into account the presence of HPV, the type of treatment, the subregion of the tonsils vs. the base of the tongue and the disease stage at the time of diagnosis, was revealed to not be influenced by the aforementioned variables. The data are consistent with previous studies, where the role of HPV HR OSCC and QoL in general, one year following treatment, was not able to be significantly distinguished from the HPV-negative role. The tissue samples analyzed in the current study, including pathology at an advanced-stage and with associated long-term patient survival, considered patients from 5--16 years following their treatment. Therefore, the results and the time gap indicate that the only significant variable affecting the QoL is the age of the patient.

The results of the present study determined that the long-term QoL of patients with HPV-associated advanced-stage oropharyngeal squamous cell cancer is as equally compromised as non-HPV-associated oropharyngeal squamous cell cancer. It is understood that patients with HPV-associated oropharyngeal cancer have a longer life expectancy and, therefore, may live longer but also experience the toxic effects of the treatment for longer ([@b34-ol-0-0-6152]). Therefore, developing and implementing a deintensified form of treatment for HPV-associated oropharyngeal cancer is justified.

Future studies may consider a further expansion of the sample size, a consensus on the methods used to identify HPV and comparisons with the results of various other studies. Further studies are required in order to investigate the use of deintensified treatments that do not compromise results, but are able to reduce the risk of adverse effects and the deterioration of QoL.

###### 

Clinicopathological characteristics of patients with advanced oropharyngeal carcinoma.

  No.   Name   Gender   Age   Location                                          Year of diagnosis   Treatment                         TNM      Stage   HPV
  ----- ------ -------- ----- ------------------------------------------------- ------------------- --------------------------------- -------- ------- -----
    1   A1     M        71    Bilateral tonsil-base of the tongue soft palate   2008                CTRT+SG                           T3N2b    IV      N
    2   A2     M        66    Tonsil-base of the tongue                         2008                CTRT+SG                           T2N2b    IV      P
    3   A3     M        64    Tonsil                                            2005                CTRT+SG                           T2N1     III     P
    4   A4     M        56    Tonsil                                            2009                CTRT +SG                          T2N2b    IV      P
    5   A5     M        56    Tonsil-base of the tongue                         2007                CTRT+SG                           T4aN2b   IV      N
    6   A6     F        57    Tonsil-base of the tongue Trigone-mandible        2010                CTRT+SG                           T3N2     IV      P
    7   A7     M        60    Tongue-oropharynx                                 2004                CTRT+SG                           T4aN2b   IV      P
    8   A8     M        57    Tonsil                                            2008                SG                                T1N1     III     N
    9   A9     M        52    Base of the tongue-Trigone                        2010                SG                                T3N0     III     N
  10    A10    F        56    Trigone-Tonsil-Bse of the tongue                  2006                CTRT+SG                           T3N1     III     N
  11    A11    F        73    Tonsil                                            2010                CTRT+SG                           T2N2b    IV      P
  12    A12    M        68    Tonsil-base of the tongue                         2007                CTRT+SG                           T3N2c    IV      P
  13    B1     F        65    base of the tongue                                2006                SG+RT                             T2N2     IV      P
  14    B2     M        69    Tonsil                                            2003                SG+RT                             T2N2     IV      N
  15    B3     M        56    Base of the tongue                                2006                SG+RT                             T3N1     III     N
  16    B4     F        46    Base of the tongue+tongue                         2004                SG                                T2N1     III     P
  17    B5     M        60    Base of the tongue                                2006                SG on head and neck and lung+RT   T3N0     III     N
  18    B6     M        58    Base of the tongue                                2003                CTRT                              T4N2b    IV      N
  19    B7     F        62    Base of the tongue                                2003                SG                                T2N1     III     N
  20    B8     M        50    Bilateral tonsil+velum                            2002                SG+RT                             T3N2b    IV      N
  21    B9     F        58    Tonsil                                            2003                SG+RT                             T3N2     IV      N
  22    B10    M        53    Base of the tongue                                2000                SG+RT                             T3N2     IV      P
  23    B11    F        65    Tonsil                                            2001                SG                                T1N1     III     N
  24    B12    F        65    Tonsil                                            2000                SG                                T2N1     III     N
  25    B13    M        52    Tonsil-base of the tongue                         2000                SG+RT                             T3N2     IV      P
  26    B14    M        54    Base of the tongue                                2000                SG+RT                             T3N2     IV      P
  27    B15    M        46    Base of the tongue                                2001                SG                                T1N1     III     P
  28    B16    M        58    Base of the tongue                                2000                SG                                T2N1     III     N
  29    B17    M        68    Tonsil                                            2002                SG                                T2N1     III     N
  30    B18    M        71    Tonsil                                            2007                RT                                T3N2     IV      N
  31    B19    M        75    Tonsil                                            2007                SG+RT                             T1N2a    IV      N
  32    B20    F        70    Base of the tongue                                2007                SG+RT                             T1N2a    IV      N
  33    B21    M        58    Base of the tongue                                2008                SG                                T1N1     III     P
  34    B22    M        55    Tonsil (+ 2005,2015)                              2008                SG+RT                             T1N1     III     N
  35    B23    M        55    Base of the tongue                                2009                SG+RT                             T2N2a    IV      P
  36    B24    M        79    Base of the tongue                                2010                CTRT                              T2N2     IV      N
  37    B25    F        60    Tonsil                                            2008                CTRT                              T2N1     III     P
  38    B26    M        58    Tonsil                                            2009                CTRT                              T4aN2b   IV      N
  39    B27    M        63    Tonsil                                            2009                CTRT+neck dissection              T4N3     IV      N
  40    B28    M        66    Base of the tongue                                2010                CTRT+neck dissection              T3N2b    IV      N
  41    B29    F        40    Tonsil                                            2008                CTRT+neck dissection              T1N2     IV      P
  42    C1     F        68    Left tonsil                                       2009                CTRT                              T3N2c    IV      P
  43    C2     M        60    Tonsil-right base of the tongue                   2009                CTRT                              T4N2b    IV      P
  44    C3     M        64    Tonsil                                            2004                CTRT                              T4N0     IV      N
  45    C4     M        71    Right tonsil                                      2007                CTRT                              T1N2b    IV      N
  46    C5     M        49    Base of the tongue                                1999                SG+RT                             T1N2b    IV      N
  47    C6     M        54    Base of the tongue                                2003                CTRT                              T4N1     IV      N
  48    C7     F        59    Tonsil                                            2000                CTRT                              T3N2a    IV      N

HPV, human papilloma virus; CTRT, chemotherapy-radiotherapy; TNM, tumor-node-metastasis; SG, surgery; P, positive; N, negative.

###### 

Analysis of the cohort of patients with advanced oropharyngeal carcinoma with regards to age.

  Factor                                     Age, years old
  ------------------------------------------ ----------------
  Average patient age                        69.74
  SD of age                                  7.83
  Min age                                    46.68
  Max age                                    83.41
  Average age at the time of the diagnosis   60.33
  SD of age at the time of the diagnosis     8.11
  Min age at the time of the diagnosis       40
  Max age at the time of the diagnosis       79

SD, standard deviation.

###### 

Results of EORTC QLQ C30 and H&N35.

  Scale                           Average   Standard deviation   Median   Range
  ------------------------------- --------- -------------------- -------- -----------
  QLQ-C30                                                                 
    Global Quality of Life        70.7      26.7                 75       0--100
    Physical functioning          82.4      18.1                 86.7     33.3--100
    Role functioning              85.8      23.3                 100      0--100
    Emotional functioning         80.9      21.6                 91.7     16.6--100
    Cognitive functioning         89.2      19                   100      16.6--100
    Social functioning            82.3      26.3                 100      0--100
    Fatigue                       17.8      18.6                 11.1     0--66.7
    Nausea and vomiting           1         5.3                  0        0--33.3
    Pain                          14.2      23.1                 0        0--83.3
    Dyspnea                       10.4      23                   0        0--100
    Insomnia                      20.1      26.4                 0        0--100
    Appetite loss                 9         21.5                 0        0--100
    Constipation                  18.8      26.5                 0        0--100
    Diarrhea                      0.7       4.8                  0        0--33.3
    Financial difficulties        19.4      30.6                 0        0--100
  QLQ-N&H35                                                               
    Pain                          6.4       11.8                 0        0--58.3
    Swallowing                    16.6      17.8                 12.5     0--66.7
    Sensing problems              18.4      23.6                 16.7     0--100
    Speech problems               14.6      17.6                 11.1     0--77.8
    Trouble with social eating    12.2      17.9                 8.3      0--75
    Trouble with social contact   9.6       17.2                 0        0--73.3
    Sexual life                   26.7      36.2                 0        0--100
    Teeth                         31.3      33.3                 33.3     0--100
    Opening mouth                 12.5      26.3                 0        0--100
    Dry mouth                     41        39.6                 33.3     0--100
    Sticky saliva                 31.9      38.3                 16.7     0--100
    Coughing                      17.4      26.6                 0        0--100
    Feeling ill                   4.1       14.78                0        0--66.7
    Use of pain killers           31.3      46.8                 0        0--100
    Nutritional supplement use    22.9      42.4                 0        0--100
    Feeding tube                  2.1       14.4                 0        0--100
    Weight loss                   14.6      35.7                 0        0--100
    Weight gain                   25        43.8                 0        0--100

EORTC, European Organization for the Research and Treatment of Cancer; QLQ C30, quality of life questionnaire-core 30; H&N35, specific questionnaire for the head and neck area.

###### 

GLM-MANOVA test of the effects of the clinical and demographic variables on EORTC QLQ-C30 and H&N35 scales.

  A, Dependent variables: QLQ-C30 scales                                        
  ------------------------------------------ ------- ------ ---- ------ ------- ----
  HPV                                        0.662   1.09   15   32.0   0.402   48
  Treatment                                  0.240   1.19   45   86.9   0.239   47
  Stage                                      0.897   0.25   15   32.0   0.997   48
  Sex                                        0.711   0.87   15   32.0   0.605   48
  Age group                                  0.429   2.84   15   32.0   0.007   48
                                                                                
  B, Dependent variables: QLQ-H&N35 scales                                      
                                                                                
  HPV                                        0.737   0.57   18   29.0   0.889   48
                                                                                
  Treatment                                  0.275   0.79   54   78.3   0.824   47
  Stage                                      0.744   0.55   18   29     0.904   48
  Gender                                     0.605   1.05   18   29     0.438   48
  Age group                                  0.672   0.79   18   29     0.698   48

Reported models are unifactorial (i.e., a separate MANOVA was performed for each independent variable). All the analyses were performed on 48 patients, with the exception of those in which the independent variable was treatment, which were performed on 47 patients. MANOVA, multivariate analysis of variance; EORTC, European Organization for the Research and Treatment of Cancer; QLQ-C30, quality of life questionnaire-core 30; H&N35, specific questionnaire for the head and neck area; HPV, human papilloma virus; df, degrees of freedom.

###### 

Follow-up t-tests to evaluate the effect of age on QLQ-C30 scales.

  QoL-C30 scale             Average \<60 years   Average ≥60 years   t        df       P-value
  ------------------------- -------------------- ------------------- -------- -------- ---------
  Overall quality of life   72.9                 68.4                0.582    45.657   0.564
  Physical functioning      89.2                 75.6                2.793    40.939   0.008
  Role functioning          93.1                 78.5                2.259    33.301   0.031
  Emotional functioning     76.7                 85.1                −1.348   43.555   0.185
  Cognitive functioning     92.4                 86.1                1.144    45.995   0.258
  Social functioning        79.9                 84.7                −0.637   44.086   0.528
  Fatigue                   16.2                 19.4                −0.600   45.191   0.552
  Nausea or vomiting        0                    2.1                 −1.366   23.000   0.185
  Pain                      11.1                 17.4                −0.938   45.814   0.353
  Dyspnea                   6.9                  13.9                −1.049   32.731   0.302
  Insomnia                  20.8                 19.4                0.180    44.288   0.858
  Appetite loss             15.3                 2.8                 2.089    28.216   0.046
  Constipation              8.3                  29.2                −2.930   37.311   0.006
  Diarrhea                  0                    1.4                 −1.000   23.000   0.328
  Financial difficulties    20.8                 18.1                0.311    42.323   0.757

The analyses were performed on 48 participants. QLQ C30, quality of life questionnaire-core 30 ([@b24-ol-0-0-6152]); t, t-statistic of the unequal variance t-test; df, degrees of freedom.
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